Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2007-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/QAI.0b013e318157131cPMID 17721395
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

  2007cited by this paper
• Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of Experience

  2006influential reference
• Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

  2006influential reference
• Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence

  2005cited by this paper
• Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.

  2005cited by this paper
• Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

  2005cited by this paper
• Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

  2004cited by this paper
• The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.

  2004cited by this paper
• Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection

  2004cited by this paper
• The prevalence of antiretroviral drug resistance in the United States

  2004cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate

  2004cited by this paper
• Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

  2004cited by this paper
• A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo

  2003cited by this paper
• Tenofovir disoproxil fumarate (Viread®) for the treatment of HIV infection

  2003cited by this paper
• Time trends in primary HIV-1 drug resistance among recently infected persons.

  2002cited by this paper
• Antiretroviral-drug resistance among patients recently infected with HIV.

  2002cited by this paper
• Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals

  2002cited by this paper
• Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection

  2002cited by this paper
• Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

  2000cited by this paper
• HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

  1996cited by this paper
• Comparative analysis of two rates.

  1985cited by this paper

• INSTIs-centered antiviral regimens for first-line treatment of HIV/AIDS: a network meta-analysis and cost-effectiveness analysis

  2025cites this paper
• HIV-1 3΄ polypurine tract mutations and integrase inhibitor resistance.

  2025cites this paper
• Impact of Integrase Strand Transfer Inhibitors on Cardiovascular Disease in People With HIV.

  2025cites this paper
• Substituent effects on Axial Chiral Compound Enantiomers: Synthesis and Crystal Structures of Axially Chiral 1,3,4-Oxadiazole Thioethers (Sulfones) based on 2,2′-Bipyridine

  2024cites this paper
• Advances in Mechanism of HIV-1 Immune Reconstitution Failure: Understanding Lymphocyte Subpopulations and Interventions for Immunological Nonresponders.

  2024cites this paper
• Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas.

  2024cites this paper
• Unveiling potent inhibitors for schistosomiasis through ligand-based drug design, molecular docking, molecular dynamics simulations and pharmacokinetics predictions

  2024cites this paper
• Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV

  2024cites this paper
• Molecular Evaluation of HIV-1 HAART Efficacy, Comparison of TDF+3TC+EFV and AZT+3TC+NVP Regimens

  2023cites this paper
• The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario

  2023cites this paper
• Complex of HIV-1 Integrase with Cellular Ku Protein: Interaction Interface and Search for Inhibitors

  2022cites this paper
• EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water

  2022cites this paper
• A numerical efficient splitting method for the solution of HIV time periodic reaction-diffusion model having spatial heterogeneity

  2022cites this paper
• Stochastic perturbation to 2-LTR dynamical model in HIV infected patients

  2022cites this paper
• Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance

  2022cites this paper
• Analysis of HIV latent infection model with multiple infection stages and different drug classes

  2022cites this paper
• Prevention of mother-to-child HIV transmission: from the first stages to the possibility of elimination

  2021cites this paper
• Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist.

  2021cites this paper
• Dual Antiretroviral Therapy—All Quiet Beneath the Surface?

  2021cites this paper
• Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach

  2021cites this paper
• Time periodic reaction–diffusion equations for modeling 2-LTR dynamics in HIV-infected patients

  2021cites this paper
• Antirétroviraux

  2021cites this paper
• A Bayesian nonparametric approach for inferring drug combination effects on mental health in people with HIV

  2020cites this paper
• Integrase Strand Transfer Inhibitors are associated with lower risk of incident Cardiovascular Disease in People Living with HIV.

  2020cites this paper
• Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase

  2020cites this paper
• Recent Advances in the Development of Integrase Inhibitors for HIV Treatment

  2020cites this paper
• Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial

  2020cites this paper
• A 35-Year Review of Pre-Clinical HIV Therapeutics Research Reported by NIH ChemDB: Influences of Target Discoveries, Drug Approvals and Research Funding

  2020cites this paper
• Ethnopharmacology, Pharmacology and Phytochemistry of Aristolochia bracteolata Lam: A Review of an Antimalarial Plant

  2020cites this paper
• Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase

  2020cites this paper
• Role of Gamma Glutamyltransferase and Alkaline Phosphatase Assay in Enzymatic Panel for Hepatobiliary Function in Patients Attending Kibungo Hospital, Rwanda

  2020cites this paper
• Discovery of 4‐oxoquinolines, a new chemical class of anti‐HIV‐1 compounds

  2019cites this paper
• Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.

  2019cites this paper
• Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.

  2019cites this paper
• Comparison of Antiretroviral Therapy Regimens With Regard to Virological and Immunological Response in Treatment-Naive HIV/AIDS Patients

  2019cites this paper
• Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence

  2019cites this paper
• HIV Treatment Strategies – The role of integrase strand transfer inhibitors

  2019influential citation
• Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

  2019cites this paper
• Infection and Drug Resistance Dovepress

  2019cites this paper
• O papel do dolutegravir na terapia antiretroviral

  2019cites this paper
• Computational approaches for improving treatment and prevention of viral infections

  2019cites this paper
• Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats

  2018cites this paper
• Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system

  2018cites this paper
• Sustained Sexual Behavior Change After Acute HIV Diagnosis in Malawi

  2018cites this paper
• Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase

  2018cites this paper
• Oseltamivir‐zanamivir combination therapy suppresses drug‐resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system

  2018cites this paper
• Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance

  2018cites this paper
• La era de los inhibidores de integrasa en el tratamiento del VIH/Sida

  2018cites this paper
• Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada

  2018cites this paper
• Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patients

  2018cites this paper
• Nucleic acid amplification of HIV-1 integrase sequence subtypes CRF01_AE and B for development of HIV anti-integrase drug resistance genotyping assay

  2017cites this paper
• SECONDARY METABOLITES AND ANTIOXIDANT PROPERTIES OFSOME HERBS AND SPICES (THYMUS VULGARIS, CAPSICUM ANNUM AND ALLIUM SATIVUM)

  2017cites this paper
• A Four-Drug Induction Therapy Including Raltegravir for the Treatment ofNaïve HIV-Infected Patients

  2017cites this paper
• Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults

  2017cites this paper
• Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial

  2017cites this paper
• Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

  2017cites this paper
• Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

  2017cites this paper
• 152 – Drugs for HIV Infection

  2017cites this paper
• Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy.

  2017cites this paper
• Association of the HLA-B*53: 01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir

  2017cites this paper
• Virologic outcomes in early antiretroviral treatment: HPTN 052

  2017cites this paper
• Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure

  2017cites this paper
• Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens

  2017cites this paper
• Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization

  2017cites this paper
• Asymmetric biosynthesis of intermediates of anti-HIV drugs

  2017cites this paper
• Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

  2017cites this paper
• Dynamics of an HIV Model with Multiple Infection Stages and Treatment with Different Drug Classes

  2016influential citation
• Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice

  2016cites this paper
• Caractérisation de l’effet des inhibiteurs allostériques de l’interaction IN-LEDGF/p75 (INLAIs) sur la réplication du VIH-1 et du SIV

  2016cites this paper
• Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.

  2016cites this paper
• Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.

  2016cites this paper
• Safety of zidovudine dose reduction in treatment‐naïve HIV infected patients. A randomized controlled study (MiniZID)

  2016cites this paper
• Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials

  2016cites this paper
• P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load

  2016cites this paper
• The Global Health Impact Index: Promoting Global Health

  2015cites this paper
• Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

  2015cites this paper
• Pharmacokinetic Determinants of Virological Response to Raltegravir in the In Vitro Pharmacodynamic Hollow-Fiber Infection Model System

  2015cites this paper
• Five-drug antiretroviral therapy for primary HIV infection?

  2015cites this paper
• Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Sketching the historical development of pyrimidones as the inhibitors of the HIV integrase.

  2015cites this paper
• G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance.

  2015cites this paper
• Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2015cites this paper
• Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection

  2015cites this paper
• HIV Shedding from Male Circumcision Wounds in HIV-Infected Men: A Prospective Cohort Study

  2015cites this paper
• Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance In Vitro

  2015cites this paper
• Using HAART to Decrease Peri-operative HIV-1 Transmission Risk: Response to Papendorp and van den Berk

  2015cites this paper
• Clinical impact of HIV-1 resistance against nonnucleoside analogue reverse transcriptase Inhibitors. Impacte clínic de la resistència del VIH-1 als inhibidors de la transcriptassa inversa no anàlegs de nucleòsids

  2015cites this paper
• Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations

  2015cites this paper
• Development and validation of analytical methods for related substances from active pharmaceutical ingredient using HPLC technique

  2015cites this paper
• Resistance against inhibitors of HIV-1 entry into target cells

  2015cites this paper
• Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?

  2015cites this paper
• Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy

  2015cites this paper
• Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials

  2015cites this paper
• Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)

  2015cites this paper
• Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease

  2015influential citation
• Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

  2015cites this paper
• The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

  2014cites this paper
• A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma.

  2014cites this paper